| |
| |
|
| Insider
Information: |
Cundy Kenneth C |
| Relationship: |
Chief Scientific Officer |
| City: |
Santa Clara |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
47,519 |
|
|
Indirect Shares
|
700 |
|
|
| Direct
Value |
$8,103 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
48,219 |
|
|
| Total
Value |
$8,103 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Xenoport Inc |
XNPT |
SVP, Preclinical Devel... |
2012-01-30 |
37,519 |
2010-02-24 |
700 |
Premium* |
|
|
Cohbar Inc |
CWBR |
Chief Scientific Officer |
2021-08-11 |
10,000 |
2015-05-22 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
131 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XNPT |
Xenoport Inc |
SVP, Preclinical DevelopmentOf |
• – – |
2005-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
54,628 |
|
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2007-04-26 |
4 |
AS |
$44.24 |
$4,424 |
D/D |
(100) |
53,211 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2009-01-02 |
4 |
AS |
$27.32 |
$2,732 |
D/D |
(100) |
10,198 |
0 |
- |
|
| CWBR |
Cohbar Inc |
Chief Scientific Officer |
• – – |
2019-10-28 |
4 |
AS |
$1.90 |
$196 |
D/D |
(103) |
10,000 |
0 |
- |
|
| CWBR |
Cohbar Inc |
Chief Scientific Officer |
• – – |
2019-10-28 |
4 |
OE |
$1.90 |
$196 |
D/D |
103 |
10,103 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2009-01-30 |
4 |
D |
$26.12 |
$5,825 |
D/D |
(223) |
12,370 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2011-01-31 |
4 |
D |
$7.88 |
$2,072 |
D/D |
(263) |
19,574 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2010-02-01 |
4 |
D |
$18.50 |
$4,977 |
D/D |
(269) |
14,861 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2008-03-03 |
4 |
AS |
$50.35 |
$15,191 |
D/D |
(300) |
13,945 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2009-02-02 |
4 |
AS |
$26.90 |
$8,085 |
D/D |
(300) |
12,370 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2009-02-17 |
4 |
D |
$26.73 |
$9,944 |
D/D |
(372) |
13,040 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2008-02-19 |
4 |
D |
$53.96 |
$20,127 |
D/D |
(373) |
16,945 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2011-01-13 |
4 |
D |
$9.16 |
$4,818 |
D/D |
(526) |
18,488 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2011-01-28 |
4 |
D |
$7.80 |
$4,103 |
D/D |
(526) |
19,212 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2010-01-28 |
4 |
D |
$18.55 |
$9,980 |
D/D |
(538) |
14,505 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2009-03-25 |
4 |
AS |
$22.00 |
$11,968 |
D/D |
(544) |
13,040 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2009-03-25 |
4 |
OE |
$1.80 |
$979 |
D/D |
544 |
13,584 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2009-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
625 |
12,593 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
625 |
15,130 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2011-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
625 |
19,837 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2008-06-02 |
4 |
OE |
$1.50 |
$977 |
D/D |
651 |
11,198 |
0 |
- |
|
| XNPT |
Xenoport Inc |
officerTitle |
• – – |
2005-11-28 |
4 |
B |
$13.00 |
$9,100 |
I/I |
700 |
700 |
1.99 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2010-02-24 |
4 |
D |
$8.02 |
$5,975 |
D/D |
(745) |
16,201 |
0 |
- |
|
| XNPT |
Xenoport Inc |
SVP, Preclinical Development |
• – – |
2012-01-30 |
4 |
D |
$4.16 |
$3,261 |
D/D |
(784) |
37,519 |
0 |
- |
|
| CWBR |
Cohbar Inc |
Chief Scientific Officer |
• – – |
2019-10-29 |
4 |
AS |
$1.90 |
$1,524 |
D/D |
(802) |
10,000 |
0 |
- |
|
131 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
